Cover page of the “Journal of Cosmetic Dermatology” (USA), an international academic journal of cosmetic dermatology and human clinical sciences.
Mediplus Pharma Inc. (Representative Director Kenji Ito, head office: Shibuya-ku, Tokyo) announces that the article on Mediplus Pharma’s patented ingredient: ozonized glycerin titled “Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin” was accepted into the American “Journal of Cosmetic Dermatology,” and used as the cover of the July 2022 issue of “Journal of Cosmetic Dermatology.”
Video abstract of the paper
Journal of Cosmetic Dermatology URL : https://onlinelibrary.wiley.com/doi/10.1111/jocd.1500
What is the Journal of Cosmetic Dermatology?
The Journal of Cosmetic Dermatology (JCD) is the official journal of the International Academy of Cosmetic Dermatology (IACD) and the Canadian Association of Aesthetic Medicine (CAAM).
The Journal primarily publishes high-quality, peer-reviewed* articles regarding innovative cosmetic dermatology globally with the aim of ‘promoting the highest standards of care techniques” in cosmetic dermatology.
Published monthly, the JCD promotes the ongoing development of professional expertise, acts as an encyclopedia of accumulated scientific research and innovative technology, and is one of only a few journals specializing in cosmetic dermatology and human clinical sciences in the world.
The parent organization, John Wiley & Sons, Ltd. (abbreviated to Wiley, NYSE: JW.A) is one of the world’s oldest independent publishing companies, founded in 1807 (215 years ago).
Wiley is a company that publishes a broad range of academic books related to the science, technology, and engineering fields with its headquarters located in New Jersey in the United States of America.
*Peer-review is the evaluation and examination by experts in the same field. An expert in the same field examines the paper to determine whether it meets the standards of the publisher.
■ Initiatives involving Mediplus Pharma’s patented ingredient: Ozonized Glycerin
Mediplus Pharma’s article “Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin” was accepted into the global “Journal of Cosmetic Dermatology” (USA) and used as the journal cover (https://onlinelibrary.wiley.com/toc/14732165/2022/21/7）.
Ozonized Glycerin was independently developed by Mediplus Pharma Inc. (formerly VMC Inc.) and patented in 2004. To date, research results on ozonized glycerin have been published in over 100 articles and conference presentations.
With the acceptance of the most recent trial results reported in “ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin,” which has drawn attention and voices of expectation from many directions about the innovative technology and effectiveness that will shock the industry, the article was used as the cover page of the July 2022 issue of “Journal of Cosmetic Dermatology.”
Furthermore, this ingredient, “ozonized glycerin,” has been used in the formulation of basic skin-care products from “Fibonacci” for consumers in Japan.
■ How does ozonized glycerin “make oxidization your friend” as recognized by specialized dermatology journals?
The Director and CTO (chief technical officer) at Mediplus Pharma Gotaro Shiota has investigated the unknown possibilities that ozonized glycerin is widely effective and safe, and makes use of oxidization, which had thus far been generally considered the enemy of beauty.
With the acceptance of the most recent trial results reported in “ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin,” which has drawn attention and voices of expectations from many directions about the innovative technology and effectiveness that will shock the industry, the article was used as the cover page of the July 2022 issue of “ Journal of Cosmetic Dermatology “.
From this point forward, it can be expected that ozonized glycerin will proceed to become an ingredient that draws attention worldwide as it is a more eco-friendly, and sustainable material.
Ozonized Glycerin test results
- Mechanism underlying the utilization of oxidization.
- Test results of direct melanin degradation by ozonized glycerin.
- Results of Fibonacci’s human clinical trials on the effect on dark spots.
■ Future initiatives
At Mediplus Pharma, we will move forward with various research and development using ozonized glycerin, with the hope of delivering new information and value quickly to all through many new discoveries and creations.
Furthermore, to share the usefulness and innovative technology of ozonized glycerin throughout the world, we will proactively participate in international conferences and meetings of technical expert related to cosmetic dermatology worldwide.
fibonacci official site＞＞https://fibonacci.jp/